IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma

IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma

Abstract Osteosarcoma (OS) is the most common primary malignant bone tumor. However, the therapeutic results of the advanced cases at the first visit were still extremely poor. Therefore, more effective therapeutic options based on molecular profiling of OS are needed. In this study, we investigated...

Full description

Bibliographic Details
Main Authors: Keita Sasa, Tsuyoshi Saito, Taisei Kurihara, Nobuhiko Hasegawa, Kei Sano, Daisuke Kubota, Keisuke Akaike, Taketo Okubo, Takuo Hayashi, Tatsuya Takagi, Takashi Yao, Muneaki Ishijima, Yoshiyuki Suehara
Format: Article
Language:English
Published: Springer 2021-11-01
Series:Discover Oncology
Subjects:
Osteosarcoma
ER stress
IRE1α-XBP1 pathway
Online Access:https://doi.org/10.1007/s12672-021-00453-2

Internet

https://doi.org/10.1007/s12672-021-00453-2

Similar Items